For Doctors in a Hurry
- Clinicians lack comparative data on how bariatric surgery and glucagon-like peptide-1 receptor agonists affect long-term cardiovascular risk in patients with obesity.
- The researchers conducted a retrospective cohort study of 812 adults with obesity who underwent metabolic surgery or initiated pharmacologic therapy.
- At one year, metabolic surgery led to a significantly greater reduction in lifetime cardiovascular risk compared to medication, -8.6% versus -1.7%.
- The authors concluded that metabolic surgery provides superior improvements in weight loss and lipid profiles, resulting in lower estimated lifetime cardiovascular risk.
- These findings suggest that clinicians should consider metabolic surgery as a more effective intervention for long-term cardiovascular risk reduction in eligible patients.
Divergent Paths in Long-Term Cardiovascular Risk Mitigation
Obesity remains a primary driver of atherosclerotic cardiovascular disease, necessitating aggressive intervention to manage metabolic and inflammatory pathways [1]. While lifestyle modifications often yield modest results, metabolic and bariatric surgery has historically served as the benchmark for sustained weight loss, with long-term data demonstrating a reduction in all-cause mortality (adjusted hazard ratio 0.71, 95% confidence interval 0.54 to 0.92) compared to usual care [2, 3]. The clinical landscape has shifted with the emergence of glucagon-like peptide-1 receptor agonists, which offer potent pharmacological alternatives for weight management and the reduction of major adverse cardiovascular events (a composite clinical endpoint typically including myocardial infarction, stroke, and cardiovascular death) [4, 5]. Current guidelines emphasize early risk factor modification to prevent these events, yet the comparative durability of surgical versus pharmacological strategies remains a point of clinical debate [6]. Recent meta-analyses of observational data suggest that bariatric surgery is associated with a 35% lower risk of major adverse cardiovascular events (hazard ratio 0.65, 95% confidence interval 0.51 to 0.83) when compared directly to glucagon-like peptide-1 receptor agonist therapy [7]. A new study now provides a direct comparison of these two modalities, focusing on their respective impacts on projected cardiovascular risk over a patient's lifetime.
Real-World Comparison of Surgical and Pharmacological Cohorts
To evaluate how these interventions perform outside of highly controlled clinical trials, the researchers conducted a retrospective cohort study within a large tertiary health care system in the United States. The study population consisted of adults with obesity, defined as having a body mass index of 30 kg/m² or higher, who either underwent metabolic and bariatric surgery or initiated glucagon-like peptide-1 receptor agonist therapy between 2020 and 2023. By utilizing electronic health records, the authors followed participants for 12 months, providing a longitudinal assessment of clinical outcomes and immediate physiological changes. The final analysis included a total of 812 patients, providing a robust sample for comparing surgical and medical weight management strategies. Within this cohort, 579 patients underwent metabolic and bariatric surgery, while 233 patients initiated glucagon-like peptide-1 receptor agonist therapy.
At the start of the study, the researchers noted distinct demographic and clinical differences between the two groups that reflect real-world prescribing and referral patterns. Specifically, patients in the glucagon-like peptide-1 receptor agonist group were older and presented with a higher estimated baseline risk for atherosclerotic cardiovascular disease (the predicted probability of developing conditions such as myocardial infarction or stroke over a given timeframe). These baseline variations necessitated the use of multivariable linear regression models (a statistical method used to isolate the effect of the treatment by controlling for other variables like age or initial weight) to adjust for initial body mass index and cardiovascular risk. This adjustment ensured that the subsequent comparisons of 1-year outcomes were statistically rigorous and not merely a reflection of the patients' health status at the time of enrollment.
Short-Term Parity vs Long-Term Divergence in Risk Scores
The researchers focused on 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease risk as the primary outcomes. These metrics represent the calculated probability of a patient experiencing a major cardiovascular event, such as a myocardial infarction or stroke, over the subsequent decade or across their remaining lifespan. At the 1-year follow-up, the data revealed that both interventions achieved comparable improvements in short-term risk profiles. Specifically, reductions in 10-year atherosclerotic cardiovascular disease risk were -0.8% for the metabolic and bariatric surgery group and -1.1% for the glucagon-like peptide-1 receptor agonist group, a difference that did not reach statistical significance (P=.36). This suggests that, within a 12-month window, both surgical and pharmacological approaches provide similar mitigation of immediate cardiovascular threats by addressing traditional risk factors.
However, a stark divergence emerged when evaluating long-term projections, which are often more relevant for younger patients with obesity who face decades of cumulative metabolic insult. Lifetime atherosclerotic cardiovascular disease risk decreased by 8.6% following metabolic and bariatric surgery compared to a 1.7% reduction following glucagon-like peptide-1 receptor agonist therapy (P<.001). Even after rigorous statistical adjustment for confounding variables, metabolic and bariatric surgery remained independently associated with a significantly greater reduction in lifetime risk compared with medication (beta -6.92; 95% confidence interval -9.22 to -4.62). These findings indicate that while both therapies offer short-term benefits, the surgical intervention may provide a more profound and sustained alteration of the patient's cardiovascular risk profile over time, potentially due to more comprehensive metabolic reprogramming.
Weight Loss and Lipid Profile Improvements
To identify the physiological drivers behind the observed risk reductions, the researchers evaluated secondary outcomes including percent total body weight loss, blood pressure, and lipid parameters. While both interventions successfully reduced patient weight, metabolic and bariatric surgery was associated with a significantly greater percent total body weight loss of -27.8% compared to -11.1% in the glucagon-like peptide-1 receptor agonist therapy group (P<.001). This substantial difference in weight loss likely contributes to the more pronounced shift in lifetime cardiovascular risk, as the surgical cohort achieved more than double the weight reduction of the pharmacological cohort within the same 12-month period.
Beyond weight loss, the study documented distinct advantages for surgical patients regarding their metabolic profiles, which are critical for preventing the progression of atherosclerosis. Metabolic and bariatric surgery resulted in larger reductions in low-density lipoprotein cholesterol, the primary atherogenic lipoprotein, compared to glucagon-like peptide-1 receptor agonist therapy. Furthermore, the surgical group experienced greater increases in high-density lipoprotein cholesterol, which provides cardioprotective effects through reverse cholesterol transport (the process by which cholesterol is removed from the peripheral tissues and transported back to the liver for excretion). These superior lipid changes, combined with the more robust weight loss, provide a mechanistic explanation for why metabolic and bariatric surgery confers a more significant reduction in lifetime atherosclerotic cardiovascular disease risk. For the practicing clinician, these results suggest that while GLP-1 receptor agonists are effective, surgery remains a more potent tool for long-term cardiovascular risk modification in appropriate candidates.
References
1. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obesity Facts. 2015. doi:10.1159/000442721
2. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. Journal of Internal Medicine. 2013. doi:10.1111/joim.12012
3. Sjöström L, Narbro K, Sjöström CD, et al. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects. New England Journal of Medicine. 2007. doi:10.1056/nejmoa066254
4. Vilsbøll T, Christensen M, Junker A, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012. doi:10.1136/bmj.d7771
5. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018. doi:10.2337/dci18-0033
6. Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021. doi:10.1093/eurheartj/ehab484
7. Cordova F, Málaga N. Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.. Surgery for Obesity and Related Diseases. 2025. doi:10.1016/j.soard.2025.11.024
